KIT and melanoma: In melanoma, it continues to serve as a valuable therapeutic option for patients with KIT mutations or amplifications, with ongoing research focused on refining patient selection, optimizing combination regimens, and integrating imatinib into evolving immunotherapy and precision oncology frameworks [55,65].